Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449427 | 0.92 | AXL (0.50) | EGFRAXLCTSCCSNK2A1 | |
| SCHEMBL3447674 | 0.91 | JAK3 (0.43) | EGFRAXLFLT3CSNK2A1 | |
| SCHEMBL3449234 | 0.91 | XDH (0.43) | EGFRAXLJAK2FLT3CSNK2A1 | |
| SCHEMBL3447741 | 0.90 | JAK3 (0.44) | EGFRAXLFLT3CSNK2A1 | |
| SCHEMBL3451174 | 0.90 | JAK3 (0.44) | EGFRAXLFLT3CSNK2A1 | |
| SCHEMBL3452344 | 0.89 | P2RY12 (0.51) | ALKSYK | |
| SCHEMBL3450592 | 0.89 | CSNK2A1 (0.42) | ALKSYKEGFRAXLJAK2 | |
| SCHEMBL3450200 | 0.88 | SMN1; SMN2 (0.44) | SYKJAK2FLT3 | |
| SCHEMBL3449527 | 0.88 | CSNK2A1 (0.43) | EGFRAXLCSNK2A1 | |
| SCHEMBL3448886 | 0.88 | KIT (0.43) | EGFRFLT3CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ALK 3205/4885SYK 804/4885EGFR 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.